komodo™

Real-World Evidence. Making a Real-World Difference.

Life Sciences companies increasingly choose to partner with Komodo Health to conduct and publish HEOR studies, citing the:

● Breadth and depth of our data. Our Healthcare Map™ encompasses the longitudinal patient journeys of **330 million patients with an average of six years of patient history**.

● Number of events we capture: **three to six times more claims per patient, 40% more clinical encounters, and 30% more unique patients** than legacy data sources.

● Inclusion of **demographic and socioeconomic data**, including geography, race, and ethnicity insights.

● **Expertise of our research team.** We partner with global RWE and HEOR teams to generate studies for publication in peer-reviewed journals and at scientific meetings.

A Sampling of Recent Research:

Studies
Khanani, A. M., Zarbin, M. A., Barakat, M. R., et al. (2022). Safety outcomes of brolucizumab in neovascular age-related macular degeneration. *JAMA Ophthalmology*. 140(1):20-28. https://doi.org/10.1001/jamaophthalmol.2021.4585
Yang J., Thompson J., Maculaitis M.C., Alvir J.M., Shelbaya A., & Kelton J.M. (2022). Real-world utilization patterns of oncology biosimilar monoclonal antibodies and their corresponding reference products, *Value in Health*, 25:6, S1
Boikos, C., Fischer, L., O'Brien, D., Vasey, J., Sylvester, G. C., & Mansi, J. A. (2021). Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018–2019 influenza season in the United States. *Clinical Infectious Diseases*, 73(3), e692–e698. https://doi.org/10.1093/cid/ciaa1944
Shelbaya, A., Kelton, J., Thompson, J., Alvir, J., Maculaitis, M., & Yang, J. (2021). Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA, *Future Oncology*, 17(30), 3941-3950, https://doi.org/10.2217/fon-2021-0618
Foster, S. A., Balkaran, B. L., Cambron-Mellott, M. J., Samaan, K., Mason, O., Ye, W., Rowland, J. C., & Jaffe, D. H. (2021). Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: A linked national survey and administrative claims database study. *Current Medical Research and Opinion*, 37(3), 443–457. https://doi.org/10.1080/03007995.2020.1865749
Sulham, K., & Reese, J. (2020). 1682. Health Resource Utilization in patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: A retrospective database analysis. *Open Forum Infectious Diseases*, 7(Supplement_1). https://doi.org/10.1093/ofid/ofaa439.1860
Jaffe, D. H., Lee, L., Huynh, S., & Haskell, T. P. (2020). Health inequalities in the use of telehealth in the United States in the lens of COVID-19. Population Health Management, 23(5), 368–377. https://doi.org/10.1089/pop.2020.0186.*Population Health Management* 23:5, 368-377, https://doi.org/10.1089/pop.2020.0186
Sireci, A., Morosini, D., & Rothenberg, S., (2021). Efficacy of immune checkpoint inhibition in RET fusion-positive non-small cell lung cancer patients, *Journal of Thoracic Oncology*, 14:10, S401, https://doi.org/10.1016/j.jtho.2019.08.816

Poster Abstracts
Strader, C., Haskell, T., Dierks, M. (2020). Representativeness of Komodo claims and identification of patients with rare disease, ICPE

Learn more about how Komodo can help you achieve your HEOR study goals by leveraging the RWE in Komodo's Healthcare Map™.